Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.39 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23514438 | 0.94 | PHGDH (0.46) | PHGDHMGLLGAATSHRKDM4E | |
| SCHEMBL23514549 | 0.94 | PHGDH (0.46) | PHGDHMGLLGAATSHRKDM4E | |
| Hydrochloric Acid SCHEMBL23499910 | 0.93 | PHGDH (0.45) | PHGDHMGLLGAATSHRKDM4E | |
| SCHEMBL23514441 | 0.89 | DPP8 (0.46) | CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL23514436 | 0.88 | PHGDH (0.38) | PHGDHMGLLGAATSHRKDM4E | |
| SCHEMBL23514538 | 0.88 | PHGDH (0.38) | PHGDHMGLLGAATSHRKDM4E | |
| Hydrochloric Acid SCHEMBL23499909 | 0.87 | DPP8 (0.39) | PHGDHMGLLGAATSHRKDM4E | |
| SCHEMBL23514532 | 0.82 | DPP8 (0.49) | CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL23514531 | 0.82 | DPP8 (0.49) | CHRM1L3MBTL3L3MBTL1 | |
| SCHEMBL23514429 | 0.78 | HSD17B10 (0.40) | PHGDHMGLLALDH1A1CHRM1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2021119475-A1 | CYSTINE DIAMIDE ANALOGS FOR CYSTINURIA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043330-A1 | Cystine Diamide Analogs For Cystinuria | CTH, CBS, SLC7A11 | PHGDH 1050/4885MGLL 1668/4885GAA 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.